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Abstract
Background: Certain urinary metabolites are the product of gut microbial or mammalian metabolism; others, such
as hippurate, are mammalian-microbial ‘co-metabolites’. It has previously been observed that Crohn’s disease (CD)
patients excrete significantly less hippurate than controls. There are two stages in the biosynthesis of this
metabolite: 1) gut microbial metabolism of dietary aromatic compounds to benzoate, and 2) subsequent
hepatorenal conjugation of benzoate with glycine, forming hippurate. Differences in such urinary co-metabolites
may therefore reflect systemic consequences of altered gut microbial metabolism, though altered host metabolic
pathways may also be involved.
Methods: It was hypothesised that reduced hippurate excretion in CD patients was due to alterations in the gut
microbiota, and not differences in dietary benzoate, nor defective host enzymatic conjugation of benzoate. 5 mg/kg
sodium benzoate were administered orally to 16 CD patients and 16 healthy controls on a low-benzoate diet.
Baseline and peak urinary hippurate excretion were measured.
Results: Baseline hippurate levels were significantly lower in the CD patients (p = 0.0009). After benzoate ingestion,
peak urinary levels of hippurate did not differ significantly between the cohorts. Consequently the relative increase
in excretion was significantly greater in CD (p = 0.0007).
Conclusions: Lower urinary hippurate levels in CD are not due to differences in dietary benzoate. A defect in the
enzymatic conjugation of benzoate in CD has been excluded, strongly implicating altered gut microbial
metabolism as the cause of decreased hippurate levels in CD.
Background
The pathogenesis of the inflammatory bowel diseases
(IBD), Crohn’s disease (CD) and ulcerative colitis (UC),
is thought to involve a genetically-determined, abnormal
host immune response to an environmental stimulus,
which is likely to be bacterial [1]. There is compelling
evidence that dysbiosis of the commensal enteric
microbes plays an important role in the pathogenesis
of these diseases [2]. Urinary metabolite levels are
strongly influenced by differences in the intestinal
microbiota, since both gut bacterial metabolism, and
shared metabolism by the host and bacterial species
(‘co-metabolism’), generate specific metabolic products
[3]. Such metabolites may therefore be used as markers
of microbial metabolic activity, reflecting systemic, func-
tional differences. This application of urinary metabolic
profiling avoids the technical difficulties, and methodo-
logical differences, found in molecular studies of the
intestinal microbiota in IBD, which have contributed to
often discrepant findings [4].
It has previously been shown that urinary levels of
the host-bacterial co-metabolite, hippurate, are signifi-
cantly lower in IBD patients when compared to healthy
control individuals, most significantly in those with CD
(p < 0.0001) [5]. These differences were independent
of medication, disease location and disease activity.
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Differences in urinary co-metabolites may reflect
altered gut microbial metabolism, though altered host
metabolic pathways may also be implicated. This study
was undertaken to investigate the biosynthesis of hippu-
rate in IBD, and specifically to clarify the influence of
the gut microbiota on urinary hippurate excretion.
The origins of hippuric acid have been investigated
since the compound was first identified in urine by Lie-
big in 1829 [6]. By the early 20th century, it had been
established that in man, hippurate is the product of the
conjugation of benzoate with glycine [7]. Later investiga-
tions revealed that this conjugation occurs via the for-
mation of an intermediate, benzoyl CoA [8], and that it
takes place in the mitochondria [9] of the liver and the
kidney [10]. Animal experiments have shown that urin-
ary hippurate excretion is modulated according to the
composition of the intestinal microbiome [11,12].
The biosynthesis of hippurate is shown diagrammati-
cally in (Figure 1). It is excreted at millimolar concentra-
tions in human urine.
Benzoate, a simple carboxylic acid, is produced from
the microbial degradation of dietary aromatic com-
pounds in the intestine, such as polyphenols, purines,
and aromatic organic acids and amino acids [13-15].
Consequently, hippurate excretion has been shown to
increase following the intake of black, green and chamo-
mile tea [16,17] as well as a diet rich in fruit and vegeta-
bles [18]. Benzoate itself is also present in various
foodstuffs and drinks. It is present naturally in most ber-
ries, fruits and fermented dairy products [19]. Due to
their antimicrobial properties, both benzoic acid and
benzoate salts may be used as preservatives. While com-
mon additives around the world, in the United Kingdom
these compounds are little used, though may be found
in soft drinks, sauces and reduced-sugar jams [20].
Early reports noted that hippurate production after
benzoate ingestion appeared to eliminate nitrogen that
would otherwise have been excreted as urea [7]. This
has been applied clinically in the management of hepatic
encephalopathy, at a dose of 10 g per day [21], and in
the treatment of patients with urea cycle enzymopathies
in therapeutic dosages of 150-500 mg/kg body weight
per day [22]. Consequently, more recent experiments
have investigated the pharmacokinetics of benzoate in
relation to its use in the treatment of disease, conclud-
ing that the substrate exhibits Michaelis-Menten kinetics
[23]. The saturable nature of this metabolism at very
high doses, due to limitations in the availability of gly-
cine, has been demonstrated [23,24].
The metabolism and elimination of low doses of
benzoate occurs rapidly, with the peak response of
urinary hippurate excretion within 1-2 hrs of ingestion
[25], for at low doses saturation of the metabolic path-
way does not occur. A World Health Organization
review suggested a No-Observed-(Adverse)-Effect-Level
of about 500 mg/kg body weight [26]. This incorpo-
rated an uncertainty factor of 100, and recommended
a provisional, chronic acceptable intake of 5 mg/kg
body weight per day.
Rationale for the study
Elucidating the metabolism and biosynthesis of hippu-
rate may provide insights into intestinal microbial dys-
biosis in IBD.
There are two steps to the production of urinary
hippurate from dietary sources. Firstly, the metabolism
of dietary aromatic compounds to benzoate by the gut
microbiota and secondly, the subsequent conjugation of
benzoate with glycine to form hippurate. Hippurate
excretion is reduced in IBD cohorts [5]. Since the most
Figure 1 The synthesis of hippurate in man.
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significant differences were observed in the CD cohort,
it was these patients rather than UC patients who were
chosen for inclusion in the current study. It is known
that the gut microbes in CD differ from the healthy
population [27], and so it was hypothesised that an
alteration in the intestinal microbiota was responsible
for the variation in hippurate excretion.
To confirm that the reduced urinary hippurate was
not due to differences in dietary benzoate, foods known
to contain high concentrations of natural benzoate, its
precursors, or benzoate as a preservative, were excluded
from the diet.
In order to exclude a defect in benzoate conjugation
in IBD as the cause of reduced urinary hippurate levels,
sodium benzoate was administered orally to groups of
healthy control individuals and CD patients. It was
hypothesised that, after benzoate ingestion, the increase
in urinary hippurate would be similar in the two
cohorts, and so the increase would be relatively greater
in the CD population, whose baseline levels of hippurate
are lower.
Methods
Subjects
The study was approved by the St. Mary’s Research
Ethics Committee (Ref 08/H0712/35) and all partici-
pants gave written, informed consent.
Patients with CD and healthy individuals were invited
to participate: vegetarians and those on a therapeutic
diet for IBD were considered ineligible, due to the likely
influence on urinary metabolite levels [18]. Patients with
significant comorbidity or a history of orofacial granulo-
matosis (the treatment of which may involve a benzo-
ate-free diet) were excluded from the study [28].
Individuals with an intercurrent illness, who were preg-
nant, or who were taking antibiotics, pre- or probiotics
were also excluded.
Studies have shown that a minority of patients with CD
has increased intestinal permeability, and it has been sug-
gested that this is correlated with disease activity [29].
Urinary hippurate levels were in fact lower in the
previously studied CD cohort [5], making increased
permeability unlikely as the cause for the observed differ-
ences. The differences in urinary hippurate also persisted
whether disease was active or quiescent. Nonetheless, all
of the CD participants in the current experiment were
studied in remission as defined by the Harvey-Bradshaw
Index [30].
Dosage of sodium benzoate used for the study
To determine the dose of benzoate to be administered
for the study, a review of the literature was undertaken
[7,23-25,31] and a pilot experiment was carried out in a
healthy control individual, using nuclear magnetic
resonance (NMR) spectroscopy to quantify urinary
hippurate as described previously [5].
It was established that, after a dose of the WHO
recommended maximum daily intake of benzoate
(5 mg/kg body weight), there was an easily detectable
increase in urinary hippurate excretion at 1 hr post-
dose, and that by 2 hrs post-dose the urinary hippurate
concentration had decreased to near baseline values.
Hence a dose of 5 mg/kg body weight was chosen.
Study Protocol
Dietary restrictions
After agreeing to participate, each individual was asked
to avoid, for 24 hrs, specific drinks and foodstuffs
known to contain high levels of benzoic acid/sodium
benzoate, or significantly to influence hippurate
synthesis through the metabolism of other organic acids.
These were: black, green or herbal teas, fruit and
carbonated drinks, berries, pickles and yoghurt.
Subjects were asked to provide a dietary and lifestyle
history, as previously described [5], to ensure that there
were no significant differences between the cohorts
which could influence results.
Sodium benzoate administration
Participants were asked to give a random, mid-stream
urine sample between 10.00 and 14.00 hrs. A dose of
5 mg/kg body weight sodium benzoate was then adminis-
tered in the form of ‘Amzoate’ Sodium Benzoate Oral
Liquid (sugar free, Dales Pharmaceuticals Ltd, UK for
Special Products Ltd, UK) and subjects were asked to
provide urine samples at 1 and 2 hrs post-dose. During
this period, they were requested not to eat or drink.
1H NMR spectroscopy of urine samples
A standard technique for the preparation of urine
samples was used [5]. This involved mixing 400 μL of
each sample with 200 μL of 0.2 M phosphate buffer,
pH 7.35, to stabilize pH. Any precipitates were removed
by subsequent centrifugation. 500 μL of supernatant
were then mixed with 50 μL of 3-trimethylsilyl-
(2,2,3,3-2H4)-1-propionate (TSP)/D2O solution. The TSP
served as an internal chemical shift reference (δ 0.00
ppm) and the D2O provided a field lock.
Samples were analysed blinded, in a random order.
1 D spectra were acquired using a JEOL 500 MHz
Eclipse+ NMR spectrometer and a standard protocol
with water presaturation. The spectral width was 15 ppm
and the number of data points acquired was 64 K. A
pulse-collect sequence was used with a 90° pulse angle.
The acquisition time was 8.74 s. A relaxation delay of
10 s (total repetition time 18.74 s) ensured full relaxation
between data collects. The 16 data collects were
summated.
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Spectra were processed using the KnowItAll Informatics
System v7.8 (Bio-Rad, Philadelphia, USA). Free induction
decays were zero-filled by a factor of two and multiplied
by an exponential window function with a 0.3 Hz line-
broadening factor prior to Fourier transformation. Spectra
were phased and a baseline correction applied.
Statistical analysis
Resonances corresponding to hippurate (δ 7.83 ppm,
doublet) were integrated and normalized to the sum of
the total spectral integral. Values were expressed as a
relative index, to the total spectral integral, corrected for
the number of contributory protons (2H); values were
also expressed as mmol/mol creatinine (δ 4.07 ppm,
singlet, 2H).
Hippurate levels in the CD and control cohorts, pre-
dose, were compared using the Mann-Whitney U test.
Comparisons between the paired samples of each indivi-
dual were made using the Wilcoxon signed rank test.
Peak hippurate excretion values for the CD and control
cohorts (1 hr post-dose) were compared using the
Mann-Whitney U test.
The peak hippurate excretion value for each partici-
pant at 1 hr post-dose was subtracted from the baseline
value, and the resulting figure, representing the absolute
difference in hippurate level, was compared between the
CD and control cohorts. The increase in hippurate level
as a percentage change was also calculated.
Dietary and lifestyle data from the cohorts were ana-
lysed using the Mann-Whitney U test for continuous
variables and Fisher’s exact test or chi-square test (as
appropriate) for categorical variables.
Results
Subject groups
Subject demographics, and details of disease for the CD
cohort [32], are shown in (Table 1). Two cohorts of 16
participants were recruited. The median age of the CD
cohort was non-significantly higher than the control
cohort. Three of the CD patients were taking no
medication.
There were no significant differences between the
groups with regards to dietary constituents, smoking,
alcohol intake or exercise. Female subjects were matched
for hormonal status.
None of the participants reported side-effects of the
benzoate ingestion.
Sample collection
For all subjects, baseline (pre-dose) and peak response
samples, at 1 hr, were collected. In both cohorts, excretion
of urinary hippurate was highest at 1 hr post-dose, and
had decreased by 2 hrs. The baseline and peak response
values were used for analysis of conjugating ability.
Baseline hippurate levels
A comparison was made between hippurate levels in the
CD and control cohorts at baseline (ie. on the diet as
described above) to negate the possible effect of foods
and drinks containing either endogenous benzoate, or
containing benzoate as a preservative, on hippurate
excretion. The results are shown in(Figure 2). As
hypothesised, significant differences were observed
Table 1 Participant characteristics
Crohn’s disease Healthy controls
Number (Male/Female) 16 (7/9) 16 (9/7)
Median [range] age (years) 42 [22-66] 33 [22-62]
Disease location L1: 2 -
L2: 6 -
L3: 8 -
Previous bowel resection 6
L1 = ileal disease, L2 = colonic disease, L3 = ileocolonic disease [32].
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Figure 2 Baseline urinary hippurate levels. Expressed relative to
total spectral integral. Median and interquartile ranges shown; p =
0.0009, Mann-Whitney U test.
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between the cohorts. The dietary restrictions of this
study in fact had little impact on urinary hippurate
values: the median values (relative to the total spectral
integral) in this study for the CD and control cohorts
were 0.39 u and 0.97 u respectively, compared to 0.38 u
and 1.04 u in the previous study [5].
Expressed as mmol/mol creatinine, results of a
similar statistical significance were obtained, hippurate
levels being lower in the CD cohort: median (inter-
quartile range) 113 (61-182) mmol/mol creatinine vs.
242 (143-365) mmol/mol creatinine, p = 0.007.
Hippurate excretion after benzoate ingestion
The increase in hippurate excretion after the ingestion
of 5 mg/kg benzoate for the CD and control groups is
shown in (Figure 3). It can be seen that the baseline
values for the control cohort were significantly greater
than those for the CD cohort, and that the values for
peak excretion at 1 hr increased more dramatically for
the CD cohort. The peak excretion values did not differ
significantly between the healthy control subjects and
CD patients (Figure 4), nor were there significant differ-
ences in the absolute difference in hippurate excretion
(calculated as the value at baseline subtracted from the
value at 1 hr, (Figure 5A). As may be inferred from
these figures, the percentage change in hippurate excre-
tion was significantly greater in the CD than the control
cohort (p = 0.0007, Figure 5B).
Expressed as mmol/mol creatinine, results were very
similar: peak excretion values did not differ (p = 0.34),
nor did the absolute differences in hippurate excretion
(p = 0.25). The percentage change in hippurate excre-
tion was greater in the CD cohort (p = 0.0006).
Discussion
This experiment has confirmed the previous finding of
reduced urinary hippurate levels in CD. It has demon-
strated that the difference in urinary hippurate
between CD and controls is not due differences in
ingested benzoate, and that patients with CD do not
have an intrinsic defect in the conjugation of benzoate
with glycine. This implicates alterations in the gut
microbiota in the observed differences in hippurate
excretion.
The influence of diet on the excretion of urinary hip-
purate has been demonstrated in previous studies
[17,18,33], emphasising the need for a careful evaluation
of dietary components when analysing urinary metabolic
data in the context of disease. As shown in (Figure 2),
the reduced excretion of hippurate in CD patients per-
sisted when foods known to contain high levels of ben-
zoic acid/sodium benzoate, or to influence hippurate
synthesis through the metabolism of other organic acids,
were excluded from the diet. This finding supports the
contention that it is the generation of benzoate via the
intestinal microbial metabolism of dietary aromatic
compounds that primarily influences the differences in
urinary hippurate between the cohorts.
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Figure 3 Increase in hippurate excretion 1 hr after benzoate
ingestion.
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Figure 4 Peak urinary hippurate levels 1 hr after benzoate
ingestion. Expressed relative to total spectral integral. Median and
interquartile ranges shown; p = 0.10, Mann-Whitney U test.
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To ensure that the reduced levels of urinary hippurate
excretion in CD were not due to an intrinsic defect in
hippurate metabolism, this experiment investigated the
ability of a CD cohort to conjugate benzoate with gly-
cine, in comparison to a healthy control cohort. A dose
of 5 mg/kg of sodium benzoate was administered to all
participants, and it was found that the peak excretion of
the metabolic product, urinary hippurate, occurred at
1 hr post-dose. There have been no published studies
investigating the excretion of hippurate after the inges-
tion of this dose of benzoate, but inspection of the data
from two previous studies, one using much higher doses
[23] and another using lower doses [25] suggests that
these results are compatible.
Kubota and Ishizaki, after studying the excretion of
hippurate after extreme doses of 40, 80 and 160 mg/kg
sodium benzoate, deduced that the biotransformation of
benzoic to hippuric acid follows saturable, or Michaelis-
Menten kinetics, with a maximum rate of biotransfor-
mation of 23 mg.kg-1.h-1 [23]. At a dose of 5 mg/kg, as
employed in the current study, the metabolically active
enzymatic components of the pathway and endogenous
glycine, rather than the substrate (benzoate), are in great
excess. Consequently, in the presence of an intact enzy-
matic conjugation pathway, the CD cohort had a rela-
tively higher production of hippurate because baseline
levels were significantly lower: as seen in (Figure 5B),
this was the salient finding of the study.
Thus, although the baseline hippurate levels were
lower in the CD cohort, the absolute difference in
hippurate excretion from baseline to peak excretion (1
hr post-benzoate administration) was not significantly
different between the cohorts, and the percentage
change in hippurate excretion of the CD patients was
significantly greater than that of the controls. These
results demonstrate that there is no deficit in the conju-
gation pathway in CD patients.
The concentration of urinary hippurate has been
shown to be modulated according to the composition of
the intestinal microbiota [11,12]. The findings of this
study provide additional evidence for the systemic
effects of an altered gut microbiome in IBD, notably
identifying a functional metabolic consequence of the
dysbiosis.
A recent study in healthy individuals has given further
insights into the powerful influence exerted by the gut
bacteria in the determination of human metabolic phe-
notypes [34]. A reduction in Clostridia spp. has been
consistently shown in IBD, and particularly CD [4]; Li
et al. [34] found a positive association between Clostri-
dia spp. and hippurate levels, which may account for
the reduced hippurate levels in our study. Future studies
correlating the urinary metabolic profiles of IBD patients
with molecular analysis of their gut microbiota would be
of great interest, representing an avenue for further
research.
Recently, Brahmachari et al. have investigated the anti-
inflammatory properties of benzoate in the context of
glial cell activation [35]. In experimental animals, benzo-
ate, but not formate, inhibited glial activation of NFB
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Figure 5 Differences between control and CD cohorts in hippurate excretion, 1 hr after benzoate ingestion. Median and interquartile
ranges shown. A. Absolute difference, expressed as a relative index, to the total spectral integral. B. Percentage change.
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and expression of inducible NO synthase and pro-inflam-
matory cytokines. Reduced synthesis of benzoate by the
intestinal microbiota in IBD may thus be implicated in the
pathogenesis of the disease; further experiments in models
of intestinal inflammation are warranted.
Conclusions
In conclusion, the biosynthesis and excretion of urinary
hippurate has been investigated in cohorts of CD
patients and healthy control individuals. The data pre-
sented provide strong evidence for the pivotal role of
the gut microbiota in the generation of urinary hippu-
rate and, moreover, their influence on the differences in
hippurate excretion between CD patients and healthy
control individuals.
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